The European Organization for Nuclear Research, known as CERN, is an intergovernmental organization that operates the largest particle physics laboratory in the world. Established in 1954, it is based in Meyrin, western suburb of Geneva, on the France–Switzerland border. It comprises 24 member states. Israel, admitted in 2013, is the only non-European full member. CERN is an official United Nations General Assembly observer.
The antiproton,
p
, is the antiparticle of the proton. Antiprotons are stable, but they are typically short-lived, since any collision with a proton will cause both particles to be annihilated in a burst of energy.
External beam radiation therapy (EBRT) is a form of radiotherapy that utilizes a high-energy collimated beam of ionizing radiation, from a source outside the body, to target and kill cancer cells. A radiotherapy beam is composed of particles which travel in a consistent direction; each radiotherapy beam consists of one type of particle intended for use in treatment, though most beams contain some contamination by other particle types.
In medicine, proton therapy, or proton radiotherapy, is a type of particle therapy that uses a beam of protons to irradiate diseased tissue, most often to treat cancer. The chief advantage of proton therapy over other types of external beam radiotherapy is that the dose of protons is deposited over a narrow range of depth; hence in minimal entry, exit, or scattered radiation dose to healthy nearby tissues.
The Proton Synchrotron is a particle accelerator at CERN. It is CERN's first synchrotron, beginning its operation in 1959. For a brief period the PS was the world's highest energy particle accelerator. It has since served as a pre-accelerator for the Intersecting Storage Rings (ISR) and the Super Proton Synchrotron (SPS), and is currently part of the Large Hadron Collider (LHC) accelerator complex. In addition to protons, PS has accelerated alpha particles, oxygen and sulfur nuclei, electrons, positrons, and antiprotons.
The Bragg peak is a pronounced peak on the Bragg curve which plots the energy loss of ionizing radiation during its travel through matter. For protons, α-rays, and other ion rays, the peak occurs immediately before the particles come to rest. It is named after William Henry Bragg, who discovered it in 1903 using alpha particles from radium, and wrote the first empirical formula for ionization energy loss per distance with Richard Kleeman.
Fast neutron therapy utilizes high energy neutrons typically between 50 and 70 MeV to treat cancer. Most fast neutron therapy beams are produced by reactors, cyclotrons (d+Be) and linear accelerators. Neutron therapy is currently available in Germany, Russia, South Africa and the United States. In the United States, one treatment center is operational, in Seattle, Washington. The Seattle center uses a cyclotron which produces a proton beam impinging upon a beryllium target.
Particle therapy is a form of external beam radiotherapy using beams of energetic neutrons, protons, or other heavier positive ions for cancer treatment. The most common type of particle therapy as of August 2021 is proton therapy.
In radiobiology, the relative biological effectiveness is the ratio of biological effectiveness of one type of ionizing radiation relative to another, given the same amount of absorbed energy. The RBE is an empirical value that varies depending on the type of ionizing radiation, the energies involved, the biological effects being considered such as cell death, and the oxygen tension of the tissues or so-called oxygen effect.
The Antiproton Decelerator (AD) is a storage ring at the CERN laboratory near Geneva. It was built from the Antiproton Collector (AC) to be a successor to the Low Energy Antiproton Ring (LEAR) and started operation in the year 2000. Antiprotons are created by impinging a proton beam from the Proton Synchrotron on a metal target. The AD decelerates the resultant antiprotons to an energy of 5.3 MeV, which are then ejected to one of several connected experiments.
The Low Energy Anti-Proton Ring (LEAR) was a particle accelerator at CERN which operated from 1982 until 1996. The ring was designed to decelerate and store antiprotons, to study the properties of antimatter and to create atoms of antihydrogen. Antiprotons for the ring were created by the CERN Proton Synchrotron via the Antiproton Collector and the Antiproton Accumulator (AA). The creation of at least nine atoms of antihydrogen were confirmed by the PS210 experiment in 1995.
The Antiproton Collector (AC) was part of the antiparticle factory at CERN designed to decelerate and store antimatter, to study the properties of antimatter and to create atoms of antihydrogen. It was built in 1986 around the existing Antiproton Accumulator (AA) to improve the antiproton production by a factor of 10. Together, the Antiproton Collector and the Antiproton Accumulator formed the so-called Antiproton Accumulator Complex (AAC).
The Antiproton Accumulator (AA) was an infrastructure connected to the Proton–Antiproton Collider – a modification of the Super Proton Synchrotron (SPS) – at CERN. The AA was built in 1979 and 1980, for the production and accumulation of antiprotons. In the SppS the antiprotons were made to collide with protons, achieving collisions at a center of mass energy of app. 540 GeV. Several experiments recorded data from the collisions, most notably the UA1 and UA2 experiment, where the W and Z bosons were discovered in 1983.
GBAR, AD-7 experiment, is a multinational collaboration at the Antiproton Decelerator of CERN.
BASE, AD-8, is a multinational collaboration at the Antiproton Decelerator facility at CERN, Geneva. The goal of the Japanese and German BASE collaboration are high-precision investigations of the fundamental properties of the antiproton, namely the charge-to-mass ratio and the magnetic moment.
Michael Holzscheiter is a German-born professor at the University of New Mexico.
The Super Proton–Antiproton Synchrotron was a particle accelerator that operated at CERN from 1981 to 1991. To operate as a proton-antiproton collider the Super Proton Synchrotron (SPS) underwent substantial modifications, altering it from a one beam synchrotron to a two-beam collider. The main experiments at the accelerator were UA1 and UA2, where the W and Z bosons were discovered in 1983. Carlo Rubbia and Simon van der Meer received the 1984 Nobel Prize in Physics for their contributions to the SppS-project, which led to the discovery of the W and Z bosons. Other experiments conducted at the SppS were UA4, UA5 and UA8.
The TRAP experiment, also known as PS196, operated at the Proton Synchrotron facility of the Low Energy Antiproton Ring (LEAR) at CERN, Geneva, from 1985 to 1996. Its main goal was to compare the mass of an antiproton and a proton by trapping these particles in the penning traps. The TRAP collaboration also measured and compared the charge-to-mass ratios of antiproton and proton. Although the data-taking period ended in 1996, the analysis of datasets continued until 2006.
Extra Low ENergy Antiproton ring (ELENA) is a 30 m hexagonal storage ring that decelerates antiproton beams and delivers it to different AD experiments. It is situated inside the Antiproton Decelerator (AD) complex at CERN, Geneva. It is designed to further decelerate the antiproton beam coming from the Antiproton decelerator to an energy of 0.1 MeV for more precise measurements. The first beam circulated ELENA on 18 November 2016. The ring is expected to be fully operational by the end of the Long Shutdown 2 (LS2) in 2021.
The PUMA AD-9 experiment, at the Antiproton decelerator (AD) facility at CERN, Geneva, aims to look into the quantum interactions and annihilation processes between the antiprotons and the exotic slow-moving nuclei. PUMA's experimental goals require about one billion trapped antiprotons made by AD and ELENA to be transported to the ISOLDE-nuclear physics facility at CERN, which will supply the exotic nuclei. Antimatter has never been transported out of the AD facility before. Designing and building a trap for this transportation is the most challenging aspect for the PUMA collaboration.
